March 14-15, 2017, Washington, DC
The Office of the National Coordinator for Health Information Technology (ONC), in collaboration with the Chamber of Digital Commerce announces a health standards and data innovation Code-a-Thon. Code-a-Thon contestants will use open source distributed ledger technology and health-specific standards to address one of the following health IT Tracks:
The Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about how bioscience discoveries move from the bench to the market. The route from discovery to market is not linear. Our panelists will relay their experiences with clinical trials, manufacturing, and marketing and will discuss how each of these aspects interacts along the way. Whether you are looking to enter the world of bench to market or are just curious about the process, this will be an informative and fun event. Moderated by Lynn Johnson Langer, Program Director, Sr. Lecturer, Johns Hopkins University, our panel includes the following individuals:
Date/Time: Thursday, February 23, 2017 6:00 p.m. – 8:00 p.m. EST
Venue: Johns Hopkins University – Montgomery Campus 106-110 A&R Building 9601 Medical Center Drive Rockville, MD 20850
Thursday, Feb 23 Vigilant Bioservices Open House (UMB Biopark) Come explore our Biorepository then join us for the UMB BioPark Holiday Happy Hour! Tours are from 1:00-5:00pm
Vigilant Bioservices provides GMP storage solutions for Biotech organizations, including outsourced temperature controlled storage and risk mitigation/business continuity services.
If you demand a return on the cost of quality, we offer peace of mind knowing your biomaterials are safe.
A group of scientists and their supporters are set to march Sunday in Boston’s Copley Square in an event they’ve dubbed “a rally to stand up for science” in the Trump years.
Inside a large nearby convention center, meanwhile, the annual meeting of the American Association for the Advancement of Science (AAAS), the United States’ largest general scientific society, has featured speeches and panel sessions further underscoring the sense that under President Trump, scientists could face wide-ranging political conflicts and challenges, and will have to decide how to meet them.
The products that make cities “smart” will be developed, tested and perhaps scaled in our backyard.
A partnership of the Herndon-based Center for Innovative Technology, D.C.-based Smart City Works and 22 CityLink, the master developer of the Gramercy District smart city planned for Ashburn, is accepting applications for its initial cohort of companies in Smart City Works @ Herndon.
OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital (“3E”).
The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease (GvHD). OncoImmune will continue clinical testing of its lead clinical product, CD24Fc, in a Phase II trial for the prevention of acute GvHD following myeloablative allogeneic hematopoietic stem cell transplant. CD24Fc has received orphan drug designation for GvHD in both the US and Europe. The funding will also support development of other immuno-oncology (IO) assets with a focus on solid tumor targeting monoclonal antibodies, cancer vaccines, and immunotherapy-related adverse events.
Host: UM BioPark & Wexford + Technology
Location: UM BioPark Life Sciences Conference Center 801 W. Baltimore Street Baltimore Maryland 21201
Time: 5:00pm to 6:30pm
Please join the BioPark’s Monthly Networking Event along with Colleagues from UMBC. Mingle with UM Venture program managers, BioPark tenants, and UMB faculty and staff.
A record number of biotechnology, life sciences and other tech-related companies with a presence in New Jersey stand to benefit from private investments spurred in part by tax credits approved by state officials last year — a sign the Garden State continues to serve as the nation’s medicine chest.
The New Jersey Economic Development Authority announced Tuesday it has approved 251 applications from “angel investors” who are eligible for state income-tax credits to help offset the more than $96 million in private funding they funneled to Garden State tech firms during 2016 — the highest annual total since the program launched three years ago.
What’s the best way to build a startup? Bootstrap it, raise little or no VC funding, and (ideally) sell it for hundreds of millions—or billions—of dollars, according to two venture capitalists.
That’s what they did at least. Andrew Farquharson, now the managing director of InCube Ventures in San Jose, CA, was the chief operating officer of Almeda, CA-based Operon Technologies when it sold to European nucleic acid company Qiagen in an all-stock deal worth around $110 million in 2000. Farquharson and his co-founders tried, but failed, to raise venture funding and instead were able to bootstrap.
Gaithersburg-based NexImmune, a biotech developing immunotherapy treatments for cancer, has been acquired by a consortium of big-name biotech veterans and investors.
